Recent Finacing
Recent Raise
Grit Bio develops tumor‑infiltrating lymphocyte (TIL) therapies for solid tumors, advancing GT101 in clinical trials in China, with StaViral, ImmuT Finder and StemTexp platforms for T‑cell engineering and expansion.
Focus Areas
Recent Investors
Funding round
Investors
